bluebird using ViroMed's antibody in CAR T therapy

ViroMed Co. Ltd. (KOSDAQ:084990) granted bluebird bio Inc. (NASDAQ:BLUE) exclusive rights to develop a chimeric antigen receptor (CAR) T cell therapy to treat solid tumors using ViroMed's humanized antibody targeting an undisclosed cancer antigen.

ViroMed received $1 million up front and is eligible for milestones totaling $48 million per product, plus tiered royalties. bluebird will be responsible for development and commercialization costs. Neither company responded to inquiries. ...